ASCENTAGE PHARM. DL-,0001 Logo
KYG0519B1023
A2PUCQ
6855.HK

ASCENTAGE PHARM. DL-,0001

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Ascentage Pharma reports H1 revenue up 29% and advances nine global registrational trials

    Ascentage Pharma posted H1 revenue of $44.5 million, up 29.3% year‑over‑year, with product sales of $41.6 million and $279.4 million in cash, supporting a runway through end‑2027. R&D spending rose to $102.8 million as the company advances nine global registrational studies for lead drugs lisaftoclax and olverembatinib; key enrollments are expected to finish by late‑2026 or early‑2027. Management said operating expenses may have peaked and expects potential multiple NDA filings in H2 2027. The company is expanding commercial capabilities outside China and highlighted Takeda’s option deal on olverembatinib that could yield up to $1.2 billion plus tiered royalties. » More on finance.yahoo.com


  • Ascentage Pharma appoints new CFO and SVP to support global growth strategy

    Ascentage Pharma has named Veet Misra, Ph.D., as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance. Both executives bring extensive experience in investment banking, corporate management, and the pharmaceutical industry. The company aims to accelerate its global strategy and integration with these appointments. » More on finance.yahoo.com

Financials

In the last quarter, ASCENTAGE PHARM. DL-,0001 had revenue of €38.44M and net profit of -€103.89M
(EUR) June 2026
YoY
Revenue 38.44M -
Gross profit 32.27M -
Net profit -103.89M -
EBITDA -90.18M -

Fundamentals

Metric Value
Market capitalization
€1.18B
Number of shares
373.17M
52-week high/low
€8.49 - €3.15
Dividends No
Beta
0.66
P/E ratio
-5.39
PEG ratio
0.53
P/B ratio
14.08
P/S ratio
12.37

Company profile

Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients with tyrosine kinase inhibitor resistant chronic phase chronic myeloid leukemia. It also has APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, which is under Phase Ib/II clinical study; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449 for non-small-cell lung carcinoma; APG-5918, an orally available and selective EED inhibitor with a best-in-class potential that is under pre-clinical stage; APG-265, which is in the IND-enabling stage for hematological malignancies and solid tumors; and UBX1967/1325 targeting Bcl family indicated for DME that is under Phase II development. Ascentage Pharma Group International has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions, which include Innovent Biologics, Inc.; National Cancer Institute; Pfizer Inc.; and Clover Biopharmaceuticals (Hong Kong) Co., Limited. The company was founded in 2009 and is headquartered in Suzhou, China.

Name
ASCENTAGE PHARM. DL-,0001
CEO
Dajun Yang
Headquarters Suzhou, js
China
Website
IPO
10/28/2019
Employees 767

Ticker symbols

Exchange Symbol
Hkse
6855.HK
Pnk
ASPHF
Frankfurt
36X.F
🍪

Parqet  uses cookies. Learn more